Introduction: A better therapy for Covid patients (15 min)
This webinar was kindly moderated by Donna van Dommelen (Catalyze) and brought together three speakers to talk about MetrioPharm’s lead compound MP1032, a host-directed broad-spectrum anti-infective agent. The webinar was part of the EU-funded iMPact project (https://covidimpact.eu/).
The webinar starts with a presentation by Dr. Wolfgang Brysch (MetrioPharm AG), about the significance of ho...
In October you attended the ECTRIMS conference for MetrioPharm. What was your impression?
Dr. Sara Schumann: The conference is immense. This year there were more than 9000 participants who met in Berlin. One can say that this international conference is the most important forum for researchers and clinicians on multiple sclerosis (MS).
Dr. Astrid Kaiser: Many MS therapies already available today were presented. Of course, we can learn a lot from these post-marketing studies as they clearly show the advantages and disadvantages of currently available drugs.
MetrioPharm presents mode of action of MP1032 at a scientific conference
The 19th Meeting of the Society for Free Radical Research International 2018 in Lisbon
What is the most important step in the development of a new drug? The successful completion of preclinical trials, the first clinical study in humans or the proof of efficacy in patients? All these steps are a precondition for approval; they show that the drug works...
“Do we all see the same thing in this picture, exactly the same? And why is that so crucial?” That’s what we asked at our Investigator Meeting in Hamburg, where employees of MetrioPharm and our study partner Bioskin met the Investigators (trial physicians) and the study nurses who will conduct our...